Qi Zhang

Qi Zhang

Auto-generated profile, based on publicly available information

Qi Zhang

Department of Pharmacology and Chemical Biology, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
QZQi Zhang
Qi Zhang
CMCheng Ma
Cheng Ma
LCLih-Shen Chin
Lih-Shen Chin
LLLian Li
Lian Li
Disease-associated glycoproteome changes identified in human brain provide new insights into Alzheimer’s disease pathogenesis.

5 April 2024 in Science Advances
Verified
Journal Article
Open access
QZQi Zhang
Qi Zhang
CMCheng Ma
Cheng Ma
LCLih-Shen Chin
Lih-Shen Chin
SPSheng Pan
Sheng Pan
LLLian Li
Lian Li
Despite the importance of protein glycosylation to brain health, current knowledge of glycosylated proteoforms or glycoforms in human brain and their alterations in Alzheimer’s disease (AD) is limited. Here, we report a proteome-wide glycoform profiling study of human AD and control brains using intact glycopeptide-based quantitative glycoproteomics coupled with systems biology. Our study identified more than 10,000 human brain N-glycoforms from nearly 1200 glycoproteins and uncovered disease signatures of altered glycoforms and glycan modifications, including reduced sialylation and N-glycan branching and elongation as well as elevated mannosylation and N-glycan truncation in AD. Network analyses revealed a higher-order organization of brain glycoproteome into networks of coregulated glycoforms and glycans and discovered glycoform and glycan modules associated with AD clinical phenotype, amyloid-β accumulation, and tau pathology. Our findings provide valuable insights into disease pathogenesis and a rich resource of glycoform and glycan changes in AD and pave the way forward for developing glycosylation-based therapies and biomarkers for AD.

30 November 2005 in Chinese Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
HLHe‐Hua Liu
He‐Hua Liu
HJHong‐Xia Jin
Hong‐Xia Jin
QZQi Zhang
Qi Zhang
YWYi‐Kang Wu
Yi‐Kang Wu
HKHye-Sook Kim
Hye-Sook Kim
YWYusuke Wataya
Yusuke Wataya

5 December 2022 in iScience
Verified
Journal Article
Open access
CWChuntao Wu
Chuntao Wu
BHBeiyuan Hu
Beiyuan Hu
LWLei Wang
Lei Wang
XWXia WU
Xia WU
HGHaitao Gu
Haitao Gu
JLJiang Long
Jiang Long
Lipid metabolism is extensively reprogrammed in pancreatic ductal adenocarcinoma (PDAC). Stearoyl-coenzyme A desaturase (SCD) is a critical lipid regulator that was unexplored in PDAC. Here, we characterized the existence of cancer-associated fibroblasts (CAFs) with high SCD expression, and revealed them as an unfavorable prognostic factor. Therefore, primary CAFs and pancreatic cancer cells were harvested and genetically labeled. The mixture of CAFs and cancer cells were co-injected into scd-/-; prkdc-/-, or hIGF1/INS-expressing zebrafish to generate patient-derived xenograft models (zPDX). The models were aligned in 3D-printed chips for semi-automatic drug administration and high-throughput scanning. The results showed that chaperoning of the SCD-high CAFs significantly improved the drug resistance of pancreatic cancer cells against gemcitabine and cisplatin, while the administration of SCD inhibitors neutralized the protective effect. Our studies revealed the prognostic and therapeutic value of stromal SCD in PDAC, and proposed the application of zPDX model chips for drug testing.

16 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
QZQi Zhang
Qi Zhang
CMCheng Ma
Cheng Ma
LCLih-Shen Chin
Lih-Shen Chin
SPSheng Pan
Sheng Pan
LLLian Li
Lian Li
Despite the importance of protein glycosylation to brain health, current knowledge of glycosylated proteoforms or glycoforms in human brain and their alterations in Alzheimer’s disease (AD) is limited. Here, we present a new paradigm of proteome-wide glycoform profiling study of human AD and control brains using intact glycopeptide-based quantitative glycoproteomics coupled with systems biology. Our study identified over 10,000 human brain N-glycoforms from nearly 1200 glycoproteins and uncovered disease signatures of altered glycoforms and glycan modifications, including reduced sialylation and N-glycan branching as well as elevated mannosylation and N-glycan truncation in AD. Network analyses revealed a higher-order organization of brain glycoproteome into networks of co-regulated glycoforms and glycans and discovered glycoform and glycan modules associated with AD clinical phenotype, amyloid-β accumulation, and tau pathology. Our findings provide novel insights and a rich resource of glycoform and glycan changes in AD and pave the way forward for developing glycosylation-based therapies and biomarkers for AD.